What are the Epstein-Barr virus (EBV) serology cut-off values for early antigen IgA, EBNA1 IgA, and viral capsid antigen IgA in AU/mL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

EBV Serology Cut-Off Values Are Not Standardized in AU/mL

There are no universally established cut-off values in AU/mL for EA IgA, EBNA1 IgA, and VCA IgA in EBV serology, as these thresholds vary significantly by assay manufacturer, clinical context, and geographic region.

Key Findings from Available Evidence

Standard Diagnostic Testing (Non-NPC Context)

The IDSA/ASM guidelines 1 recommend EBV antibody testing for IgG and IgM to VCA and EBNA but do not specify AU/mL cut-offs for IgA antibodies, as IgA testing is not part of routine EBV infectious mononucleosis diagnosis. The guidelines focus on:

  • VCA IgM presence indicating recent primary infection
  • EBNA antibodies developing 1-2+ months after primary infection
  • Over 90% of adults having IgG antibodies to VCA and EBNA

Chronic Active EBV Infection (CAEBV)

For CAEBV diagnosis, the 2005 guidelines 2 specify:

  • VCA-IgG ≥1:640 (titer, not AU/mL)
  • EA-IgG ≥1:160 (titer, not AU/mL)
  • Positive IgA antibodies to VCA and/or EA are "often demonstrated" but no specific AU/mL thresholds provided

Nasopharyngeal Carcinoma (NPC) Screening Context

This is where IgA antibodies and AU/mL units are most relevant:

Most Recent High-Quality Evidence:

  • A 2024 study 3 using prefabricated IFA showed optimal thresholds of VCA ≥1:320 or EA ≥1:10 (titers, not AU/mL) with 92.7% sensitivity and 81.2% specificity

  • A 2020 study 4 using ELISA methodology found EBNA1-IgA yielded AUC 0.962 with 91.5% sensitivity and 98.7% specificity for early-stage NPC, but specific AU/mL cut-off not reported

  • A 2008 study 5 recommended EA+EBNA-1 IgA ≥6 EU/mL (enzyme units, similar to AU) with 95.1% specificity in controls

  • A 2006 study 6 using combined EBNA1 plus VCA IgA ELISA achieved 90.1% sensitivity and 85.4% specificity, but AU/mL thresholds not specified

Critical Clinical Caveats

Assay-Specific Variability

Each commercial assay has different cut-offs. For example:

  • One study 7 using Platelia™ defined 10 AU/mL as positive for anti-mannan antibodies (different pathogen, but illustrates AU/mL variability)
  • The 2013 study 5 used 6 EU/mL for EA+EBNA-1 IgA in NPC screening

Age and Sex Considerations

  • VCA-IgA titers increase with age 8
  • 85.2% of VCA-IgA-positive individuals convert to negative during 5-year follow-up 8
  • Age- and sex-specific cut-offs should be considered but are not standardized

Clinical Context Matters

  • For routine EBV infection diagnosis: IgA antibodies are not recommended; use IgM/IgG to VCA and EBNA 1
  • For NPC screening in endemic areas: Combined EA-IgA + EBNA1-IgA testing is superior to VCA-IgA alone 5
  • For post-transplant monitoring: EBV DNA viral load is preferred over serology 9

Practical Approach

Since you are asking for specific AU/mL values:

  1. Contact your specific laboratory to obtain their assay-specific reference ranges, as these are manufacturer-dependent

  2. If using ELISA-based assays for NPC screening context:

    • Consider ≥6 EU/mL (approximately equivalent to AU/mL) for EA+EBNA1-IgA combined as a reasonable threshold based on 5
    • This achieved 95.1% specificity in controls
  3. If using immunofluorescence assays:

    • Titers (e.g., 1:320 for VCA-IgA, 1:10 for EA-IgA) are more commonly reported than AU/mL 3
  4. For non-NPC contexts:

    • IgA antibody testing with AU/mL cut-offs is not validated or recommended 1

The absence of standardized AU/mL cut-offs across the literature reflects the lack of international consensus and the assay-dependent nature of these measurements. Always interpret results in conjunction with your laboratory's validated reference ranges and the specific clinical question being addressed.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.